On September 5, 2024, the Canadian Agency for Drugs and Technologies in Health (CADTH) officially became Canada’s Drug Agency (CDA).
CDA maintains and expands on CADTH’s mandate and functions, while “developing new programs focused on appropriate use, data and analytics, and system coordination and alignment.”
The announcement also provided an update on CDA’s strategic plan and introduced members for the Appropriate Use Advisory Committee. The mandate of the Committee includes advising CDA and providing recommendations for appropriate use strategy and programming.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines outlines proposed new framework for patented medicine price review
This article provides an overview of the price review framework proposed by the PMPRB and key topics on which stakeholder feedback is sought.Read More -
Manitoba last province to introduce Biosimilars Initiative, while Ontario adds four drugs to its Biosimilar Policy
Manitoba has implemented a Biosimilars Initiative effective August 1, 2024.Read More -
PMPRB appoints Sharon Blady to Board and releases October 2024 NEWSletter
On October 17, 2024, the Minister of Health announced the appointment of Sharon Blady (the former Health Minister of Manitoba) to the Patented Medicine Prices Review Board (PMPRB).Read More